Brind.
  1. FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.

Mercier joined Gilead Sciences as Chief Commercial Officer on August 14, 2025, while expert Tyler Van Buren commented on Yeztugo's early uptake trajectory.

1 report, 1 independent Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Mercier joined Gilead Sciences as Chief Commercial Officer on August 14, 2025, while expert Tyler Van Buren commented on Yeztugo's early uptake trajectory.

Who's involved

What this event is mainly about
Gilead SciencesMercier

Keep exploring

Part of

FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • StockStoryGilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launc